These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11589821)

  • 1. The role of NNRTIs in antiretroviral combination therapy: an introduction.
    Nelson M
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():1-2. PubMed ID: 11589821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of NNRTIs in antiretroviral-experienced patients.
    Maggiolo F
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():10-7. PubMed ID: 11589823
    [No Abstract]   [Full Text] [Related]  

  • 4. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
    Torre D; Tambini R; Speranza F
    HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of NNRTIs in antiretroviral-naïve patients.
    Arribas J
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():3-9. PubMed ID: 11589822
    [No Abstract]   [Full Text] [Related]  

  • 6. [Efavirenz--comprehensive status of studies].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
    [No Abstract]   [Full Text] [Related]  

  • 7. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.
    Pérez-Elías MJ; Moreno A; Moreno S; López D; Antela A; Casado JL; Dronda F; Gutiérrez C; Quereda C; Navas E; Abraira V; Rodríguez MA
    HIV Clin Trials; 2005; 6(6):312-9. PubMed ID: 16452065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NNRTIs: a neglected class.
    Cadman J
    GMHC Treat Issues; 1998 Sep; 12(9):6-10. PubMed ID: 11365807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

  • 12. [Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():39. PubMed ID: 11373776
    [No Abstract]   [Full Text] [Related]  

  • 13. Can early failure with nevirapine be rescued with efavirenz?
    Briones C; Soriano V; Dona C; Barreiro P; González-Lahoz J
    J Acquir Immune Defic Syndr; 2000 May; 24(1):76-8. PubMed ID: 10877499
    [No Abstract]   [Full Text] [Related]  

  • 14. The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment of HIV.
    Sheran M
    HIV Clin Trials; 2005; 6(3):158-68. PubMed ID: 16192249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.
    Manfredi R; Calza L; Chiodo F
    J Acquir Immune Defic Syndr; 2004 Apr; 35(5):492-502. PubMed ID: 15021314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    De Clercq E
    Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting adherence and convenience in antiretroviral therapy.
    Lafeuillade A
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():18-24. PubMed ID: 11589824
    [No Abstract]   [Full Text] [Related]  

  • 19. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
    Martínez E; Arnaiz JA; Podzamczer D; Dalmau D; Ribera E; Domingo P; Knobel H; Riera M; Pedrol E; Force L; Llibre JM; Segura F; Richart C; Cortés C; Javaloyas M; Aranda M; Cruceta A; de Lazzari E; Gatell JM;
    N Engl J Med; 2003 Sep; 349(11):1036-46. PubMed ID: 12968087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.